Rocket Pharmaceuticals, Inc. (RCKT)
Automate Your Wheel Strategy on RCKT
With Tiblio's Option Bot, you can configure your own wheel strategy including RCKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RCKT
- Rev/Share 0.0
- Book/Share 3.7435
- PB 0.756
- Debt/Equity 0.0615
- CurrentRatio 9.1896
- ROIC -0.616
- MktCap 304898540.0
- FreeCF/Share -1.9336
- PFCF -1.4323
- PE -1.2075
- Debt/Assets 0.0538
- DivYield 0
- ROE -0.6492
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RCKT | Evercore ISI | Outperform | In-line | -- | $5 | May 30, 2025 |
| Downgrade | RCKT | Leerink Partners | Outperform | Market Perform | -- | $8 | May 28, 2025 |
| Downgrade | RCKT | Jefferies | Buy | Hold | -- | $2.5 | May 28, 2025 |
| Downgrade | RCKT | Morgan Stanley | Overweight | Equal Weight | -- | $7 | May 28, 2025 |
| Downgrade | RCKT | Goldman | Neutral | Sell | -- | $2 | May 28, 2025 |
| Downgrade | RCKT | JP Morgan | Overweight | Neutral | -- | -- | May 28, 2025 |
| Downgrade | RCKT | Needham | Buy | Hold | -- | -- | May 27, 2025 |
| Downgrade | RCKT | TD Cowen | Buy | Hold | -- | -- | May 27, 2025 |
| Initiation | RCKT | BMO Capital Markets | -- | Outperform | -- | $50 | March 12, 2025 |
| Initiation | RCKT | Wedbush | -- | Outperform | -- | $32 | Dec. 30, 2024 |
News
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Inquire about Securities Investigation
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
Ongoing Securities Investigation into Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky
Published: June 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Connect
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Published: June 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Investigation Opened on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - Contact Levi & Korsinsky
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announcing an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Fraud Investigation
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Shareholders to Reach Out
Published: June 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
Did You Suffer Losses in Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Securities Fraud Claims
Published: June 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT) Over Possible Securities Fraud
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Investors to Connect
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
Investigation Opened on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders - Contact Levi & Korsinsky
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 05, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announcing an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Potential Securities Fraud: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. (RCKT)
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Rocket Pharmaceuticals, Inc. (RCKT) Stockholders to Inquire about Securities Investigation
Published: June 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
Levi & Korsinsky Launches Fraud Investigation on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
RCKT ALERT: Ongoing Investigation Into Rocket Pharmaceuticals, Inc. - Contact Levi & Korsinsky
Published: June 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Levi & Korsinsky Investigating Whether Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors - Securities Law Violations Possible
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announcing an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Ongoing Investigation: Rocket Pharmaceuticals, Inc. (RCKT) May Have Misled Shareholders - Levi & Korsinsky Investigates
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Rocket Pharmaceuticals, Inc. (RCKT) and Encourages Stockholders to Learn More About the Investigation
Published: June 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
RCKT ACTIVE INVESTIGATION: Lost Money on Rocket Pharmaceuticals, Inc.? Contact Levi & Korsinsky Now
Published: May 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Rocket Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
RCKT ALERT: Levi & Korsinsky Investigates Rocket Pharmaceuticals, Inc. for Possible Securities Fraud Violations
Published: May 29, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals, Inc.") (NASDAQ:RCKT) concerning possible violations of federal securities laws. Rocket issued a press release on May 27, 2025, "announc[ing] an update related to RP-A501, its investigational gene therapy for Danon disease.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect
Published: May 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT). Investors who purchased Rocket securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/RCKT.
Read More
RCKT Stock Tanks on Patient Death in Danon Disease Study
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Negative
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts a clinical hold on the study.
Read More
About Rocket Pharmaceuticals, Inc. (RCKT)
- IPO Date 2015-02-18
- Website https://rocketpharma.com
- Industry Biotechnology
- CEO Dr. Gaurav D. Shah M.D.
- Employees 299